Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Common Equity (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Common Equity for 3 consecutive years, with $288.0 million as the latest value for Q1 2026.

  • Quarterly Common Equity rose 211.67% to $288.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $288.0 million through Jan 2026, up 211.67% year-over-year, with the annual reading at $205.4 million for FY2025, 198.1% up from the prior year.
  • Common Equity for Q1 2026 was $288.0 million at Kestra Medical Technologies, up from $164.1 million in the prior quarter.
  • The five-year high for Common Equity was $288.0 million in Q1 2026, with the low at -$257.9 million in Q1 2025.
  • Average Common Equity over 3 years is $13.1 million, with a median of $164.1 million recorded in 2025.
  • The sharpest move saw Common Equity plummeted 230.96% in 2025, then surged 211.67% in 2026.
  • Over 3 years, Common Equity stood at -$236.5 million in 2024, then soared by 169.37% to $164.1 million in 2025, then soared by 75.52% to $288.0 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $288.0 million, $164.1 million, and $184.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.